Overview

Safinamide Renal Impairment Trial

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of the trial is to investigate the pharmacokinetics (behaviour of the compound in the body) of safinamide in subjects with different degrees of renal impairment in comparison to matched subjects with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Newron
Newron Pharmaceuticals SPA